- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05361343
First Line Prevent Age Study (FLIPS)
To prove the effectiveness of complex wellness programs in terms of maintaining active longevity, including motivational counseling, high-intensity training, intermittent fasting, hypoxic training, as well as practices for achieving healthy sleep and mental well-being.
Clinical-instrumental, single-centre, prospective, open-label, non-randomized, sequential enrollment study with blinded endpoint analysis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Anna Ratnikova
- Phone Number: +7 921 303-15-33
- Email: ya.ashikhmin@gmail.com
Study Locations
-
-
-
Saint Petersburg, Russian Federation
- Recruiting
- First Line Health Care Resort
-
Contact:
- Anna Ratnikova
- Phone Number: +7 921 303-15-33
- Email: a.ratnikova@hcresort.ru
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women over 18;
- No significant (affecting the functional state) "active" diseases: acute diseases and exacerbations of chronic diseases;
- Interest in active longevity and willingness to participate in research.
- Signed informed consent.
Exclusion Criteria:
- Age up to 18 years;
- Severe or moderate comorbidities;
- Rheumatological (systemic / autoimmune) diseases of any severity;
- Intestinal infections (within 3 months);
- SARS / pneumonia, other diseases accompanied by systemic inflammation during the last 2 months;
- Chronic inflammatory bowel disease;
- Major surgery within the last 3 months
- Intoxication (alcohol, drugs, other toxins);
- Oncological disease (except for basalioma) out of remission;
- Persons with mental illness;
- Diabetes;
- Syndrome of obstructive sleep apnea of moderate and severe severity;
- Low adherence to lifestyle interventions, including physical activity of less than 150 minutes of aerobic activity per week (at least two days per week) or 75 minutes of vigorous exercise (at least 3 days per week).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Arm 1
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
improved endothelial function
Time Frame: First point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)
|
improvement of flow-mediated vasodilatation measured by ultrasound (cuff test)
|
First point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)
|
improved quality of night sleep
Time Frame: First point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)
|
improvement in nighttime sleep quality assessed by a Pittsburgh Sleep Quality Scale
|
First point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)
|
Reducing the degree of anxiety
Time Frame: First point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)
|
Reduction in the degree of anxiety according to the assessment of the Spielberger test
|
First point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
increased self-esteem
Time Frame: First point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)
|
increasing the level of self-esteem based on the results of the analysis of the Dembo-Rubinstein questionnaire
|
First point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)
|
improved quality of night sleep
Time Frame: First point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)
|
improvement in nighttime sleep quality assessed by a sleep indicator scale
|
First point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- FLIPS-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Aging
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
Beijing HospitalBGI-ShenzhenCompletedAging | Healthy Aging
-
Northumbria UniversityUniversity of East AngliaSuspendedSleep | Aging | Healthy AgingUnited Kingdom
-
Baskent UniversityCompleted
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
University of StirlingCompletedAging | Healthy Aging | Older Adults | AgedUnited Kingdom
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
-
Amazentis SAAtlantia Food Clinical TrialsCompletedHealthy | Healthy AgingUnited States
Clinical Trials on 1. Nutrition; 2. Physical activity; 3. Hypoxic training; 4. Menthal heals improvement
-
Hacettepe UniversityCompletedLiver Transplant DisorderTurkey
-
University of Southern CaliforniaThe Leona M. and Harry B. Helmsley Charitable TrustCompletedType1diabetesUnited States
-
PfizerCompletedHealthy | Drug InteractionBelgium
-
National Cancer Institute (NCI)Active, not recruitingAdult T Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | Ann Arbor Stage III Adult Lymphoblastic Lymphoma | Ann Arbor Stage III Childhood Lymphoblastic Lymphoma | Ann... and other conditionsUnited States, Canada, Australia, New Zealand